ELVN

Enliven Therapeutics, Inc. · NASDAQ

Performance

-2.62%

1W

-17.85%

1M

+3.43%

3M

+13.61%

6M

+71.89%

YTD

+118.86%

1Y

Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado.

Technical Analysis of ELVN 2024-12-10

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 and the Technical Score at 28, both indicating weakness, while the Oscillators Score at 40 suggests a neutral stance. Overall, the combined scores imply a cautious outlook for the stock, highlighting potential challenges ahead.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of ELVN

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.